Multiple Sclerosis Market Growth Projections 2024-2034: DelveInsight Analysis | Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Celgene Corporation, Johnson & Johnson, Biogen, Centocor, Inc

DelveInsight's "Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Multiple Sclerosis, historical and forecasted epidemiology as well as the Multiple Sclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Multiple Sclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Multiple Sclerosis Market Forecast
https://www.delveinsight.com/sample-request/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Multiple Sclerosis Market Report:
• The Multiple Sclerosis market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In May 2025, Immunic announced its intention to continue developing vidofludimus calcium (IMU-838), its investigational therapy for multiple sclerosis (MS), despite the Phase II trial not achieving its primary endpoint. Initial findings from the ongoing CALLIPER study (NCT05054140) indicated a slight benefit in an exploratory MRI-based primary measure, with a 5% annualized reduction in brain volume loss compared to placebo.
• In March 2025, The U.S. FDA has granted Priority Review to Sanofi's regulatory application for tolebrutinib, based on favorable results from the Phase III HERCULES (NCT04411641), GEMINI 1 (NCT04410978), and GEMINI 2 (NCT04410991) trials. This submission aims to secure approval for treating non-relapsing secondary progressive multiple sclerosis (nrSPMS) and focuses on slowing disability progression not linked to relapse activity in adults.
• In February 2025, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) announced the successful completion of its Phase 1 trial titled "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants." The final review by the Safety Review Committee (SRC) confirmed that Lucid-21-302 (Lucid-MS) was well-tolerated, with no safety issues or serious adverse events observed. Lucid-MS is a first-in-class, neuroprotective agent without immunomodulatory effects, currently in development for treating multiple sclerosis (MS).
• In January 2025, Pheno Therapeutics secured clinical trial authorization (CTA) from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to begin testing its small-molecule therapy, PTD802. This approval allows the launch of the first-in-human trial for PTD802, a selective antagonist of G protein-coupled receptor 17 (GPR17), aimed at enhancing remyelination in individuals with neurological conditions, especially multiple sclerosis (MS).
• In January 2025, Contineum Therapeutics, Inc. (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on novel treatments for neuroscience, inflammation, and immunology (NI&I) disorders, announced the successful completion of enrollment for its Phase 2 PIPE-307 VISTA trial. The study has enrolled 168 participants and is investigating PIPE-307, a potentially first-in-class M1 receptor antagonist, as a treatment option for relapsing-remitting multiple sclerosis (RRMS).
• In 2023, there were 728,000 prevalent cases of multiple sclerosis in the US, and this number is projected to undergo significant changes by 2034.
• In 2023, when the prevalent cases of multiple sclerosis in Germany were analyzed by gender, there were approximately 61,000 cases among males and 150,000 cases among females.
• In the UK, when multiple sclerosis cases were categorized by phenotype, a significant difference was observed, with RRMS being more prevalent than Clinically Isolated Syndrome, SPMS, and PPMS. In 2023, around 80,000 major cases of multiple sclerosis were recorded under the RRMS subtype, and these numbers are anticipated to fluctuate further during the study period from 2020 to 2034.
• In 2023, Japan recorded about 5,000 prevalent cases of multiple sclerosis, with expectations that these numbers will fluctuate further by 2034.
• Key Multiple Sclerosis Companies: Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Celgene Corporation, Johnson & Johnson, Biogen, Centocor, Inc., TG Therapeutics, Merck Healthcare KGaA, Clene Nanomedicine, Immune Response BioPharma, Pfizer, Bayer AG, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Biogen Inc., EMD Serono, Eisai Co. Ltd., Apitope, AbbVie Inc., and others
• Key Multiple Sclerosis Therapies: NeuroVax, CNM-Au8, Tolebrutinib (SAR442168), Evobrutinib/ M2951, Ublituximab, rHIgM22, CNTO 1275, Interferon beta-1a (Rebif), Fingolimod, and others
• The Multiple Sclerosis epidemiology based on gender analyzed that in the United States, the prevalence of Multiple Sclerosis is higher in females as compared to males
• The Multiple Sclerosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Multiple Sclerosis pipeline products will significantly revolutionize the Multiple Sclerosis market dynamics.
• The Multiple Sclerosis treatment market looks promising as the market is emerging with newer acute treatments that have been designated by the FDA to treat Multiple Sclerosis. However, large multicenter trials are still necessary to examine the overarching patterns of Multiple Sclerosis and treatment response as a whole.

Multiple Sclerosis Overview
AL Amyloidosis, or Primary Amyloidosis, is a rare disorder characterized by the abnormal accumulation of amyloid proteins in various tissues and organs of the body. These proteins are misfolded and deposited in tissues, impairing normal function.

Get a Free sample for the Multiple Sclerosis Market Report:
https://www.delveinsight.com/report-store/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Multiple Sclerosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Multiple Sclerosis Epidemiology Segmentation:
The Multiple Sclerosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Multiple Sclerosis
• Prevalent Cases of Multiple Sclerosis by severity
• Gender-specific Prevalence of Multiple Sclerosis
• Diagnosed Cases of Episodic and Chronic Multiple Sclerosis

Download the report to understand which factors are driving Multiple Sclerosis epidemiology trends @ Multiple Sclerosis Epidemiology Forecast
https://www.delveinsight.com/sample-request/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Multiple Sclerosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Sclerosis market or expected to get launched during the study period. The analysis covers Multiple Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Multiple Sclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Multiple Sclerosis Therapies and Key Companies
• NeuroVax: Immune Response BioPharma
• CNM-Au8: Clene Nanomedicine
• Tolebrutinib (SAR442168): Sanofi
• Evobrutinib/ M2951: Merck Healthcare KGaA
• Ublituximab: TG Therapeutics

Discover more about therapies set to grab major Multiple Sclerosis market share @ Multiple Sclerosis Treatment Market
https://www.delveinsight.com/sample-request/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Multiple Sclerosis Market Drivers
• Increasing population with Multiple Sclerosis
• Extensive approved therapies
• Wide range of R&D pipeline
• Increasing awareness

Multiple Sclerosis Market Barriers
• High cost of drugs
• High incidence of adverse events
• Patent expiration

Scope of the Multiple Sclerosis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Multiple Sclerosis Companies: Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Celgene Corporation, Johnson & Johnson, Biogen, Centocor, Inc., TG Therapeutics, Merck Healthcare KGaA, Clene Nanomedicine, Immune Response BioPharma, Pfizer, Bayer AG, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Biogen Inc., EMD Serono, Eisai Co. Ltd., Apitope, AbbVie Inc., and others
• Key Multiple Sclerosis Therapies: NeuroVax, CNM-Au8, Tolebrutinib (SAR442168), Evobrutinib/ M2951, Ublituximab, rHIgM22, CNTO 1275, Interferon beta-1a (Rebif), Fingolimod, and others
• Multiple Sclerosis Therapeutic Assessment: Multiple Sclerosis current marketed and Multiple Sclerosis emerging therapies
• Multiple Sclerosis Market Dynamics: Multiple Sclerosis market drivers and Multiple Sclerosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Multiple Sclerosis Unmet Needs, KOL's views, Analyst's views, Multiple Sclerosis Market Access and Reimbursement

To know more about Multiple Sclerosis companies working in the treatment market, visit @ Multiple Sclerosis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Multiple Sclerosis Market Report Introduction
2. Executive Summary for Multiple Sclerosis
3. SWOT analysis of Multiple Sclerosis
4. Multiple Sclerosis Patient Share (%) Overview at a Glance
5. Multiple Sclerosis Market Overview at a Glance
6. Multiple Sclerosis Disease Background and Overview
7. Multiple Sclerosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Multiple Sclerosis
9. Multiple Sclerosis Current Treatment and Medical Practices
10. Multiple Sclerosis Unmet Needs
11. Multiple Sclerosis Emerging Therapies
12. Multiple Sclerosis Market Outlook
13. Country-Wise Multiple Sclerosis Market Analysis (2020-2034)
14. Multiple Sclerosis Market Access and Reimbursement of Therapies
15. Multiple Sclerosis Market Drivers
16. Multiple Sclerosis Market Barriers
17. Multiple Sclerosis Appendix
18. Multiple Sclerosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Multiple Sclerosis Pipeline https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Multiple Sclerosis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Multiple Sclerosis market. A detailed picture of the Multiple Sclerosis pipeline landscape is provided, which includes the disease overview and Multiple Sclerosis treatment guidelines.

Multiple Sclerosis Epidemiology https://www.delveinsight.com/report-store/multiple-sclerosis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Multiple Sclerosis Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Multiple Sclerosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Cardiac Rhythm Management Devices Market: https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market
• Tumor Ablation Market: https://www.delveinsight.com/report-store/tumor-ablation-market
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• India Healthcare Report: https://www.delveinsight.com/report-store/india-healthcare-outlook-report
• Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.